Products containing specific probes for detecting alternative splice forms protected
ted Bruno Tocque President and CEO ExonHit Therapeutics. This is a significant event for ExonHit as we have been quite successful in leveraging strategic assets in multiple arenas including the therapeutic diagnostic and research tool markets ?areas in which these claims will further increase our market share.